Navamedic Secures Final Approvals for Flexilev® in All Nordic Countries

Navamedic's Milestone in the Nordic Region

Navamedic ASA has successfully streamlined its market entry into the Nordic region by obtaining final approvals for the packaging of Flexilev® in various national languages. As of August 13, 2025, Norway, Sweden, and Denmark have all granted necessary permissions, following previous advancements disclosed on June 27. Additionally, Orion Corporation, which holds the rights for Finland and the broader EU regions, has also acquired the final confirmation for navigating the Finnish market.

"We are thrilled to have received the final approvals that facilitate our entry into the Nordic market," enthused Kathrine Gamborg Andreassen, Navamedic's Chief Executive Officer. This approval marks a crucial milestone not only for Navamedic but also for patients who require tailored solutions for managing Parkinson's disease.

What is Flexilev®?

Flexilev® is a progressive treatment solution particularly designed to cater to the individual needs of Parkinson's patients. This innovative approach emphasizes the provision of precise and personalized medication, addressing the unique challenges these patients face.

A critical feature of Flexilev® is its ability to have medications with a narrow therapeutic margin administered through a method known as hyper-fractionation. This technique allows smaller, frequent doses that can enhance therapeutic outcomes for patients requiring diligent medication management.

Introduction of OraFID®

At the heart of the Flexilev® treatment system is OraFID®, a patented and state-of-the-art medical device that operates mechanically to dispense minitablets in accurate quantities. This device drastically simplifies the medication administration process, requiring just a few twists for precise delivery, ensuring patients receive exactly what they need without any margin for error.

The anticipated launch of Flexilev® in Nordic markets is scheduled for October 2025, aligning with strategic planning for broader distribution across healthcare facilities and pharmacies.

About Navamedic

Founded on the principles of quality and innovation, Navamedic ASA has positioned itself as a reliable player in the Nordic pharmaceutical landscape. The company’s commitment is not solely to generate profits but rather to enhance the quality of life for patients by providing high-quality prescription drugs, consumer health products, and vital hospital supplies within the Nordic and Benelux regions.

Navamedic places a significant emphasis on understanding the specific requirements of the markets it serves. This local insight paired with their established expertise enables the company to identify and meet the pressing health concerns in these areas, such as obesity, Parkinson's disease, and gastrointestinal issues, facilitating healthier and more fulfilled lives for individuals.

As a listed entity on the Oslo Stock Exchange since 2006, under the ticker symbol NAVA, Navamedic has consistently sought to expand its reach through in-licensing and out-licensing opportunities. This well-rounded strategy allows international firms to broaden their footprint in the Nordic markets expeditiously.

For more insights about Navamedic’s revolutionary products and initiatives, please visit Navamedic.com.

With a landscape continually evolving, Navamedic remains at the forefront, ensuring that innovative healthcare solutions are accessible to those in need across the region.